There are 1105 resources available
122TiP - Watch and wait in patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after PD-1 monoclonal antibody therapy (BASKET)
Presenter: Fang He
Session: Poster Display session
Resources:
Abstract
123TiP - Dynamic multi-omics integration modelto predict neoadjuvant therapy response in locally advanced rectal cancer
Presenter: Yandong Zhao
Session: Poster Display session
Resources:
Abstract
124TiP - Safety and efficacy of PD-1 monoclonal antibody with or without mFOLFOX6 neoadjuvant therapy in patients with local advanced deficient mismatch repair/microsatellite instability-high synchronous multiple primary colorectal cancer
Presenter: Yandong Zhao
Session: Poster Display session
Resources:
Abstract
125TiP - Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for locally advanced colorectal cancer: A single-centre, open-label, randomized controlled trial
Presenter: Shiyu Xu
Session: Poster Display session
Resources:
Abstract
135P - Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract cancer (aBTC)
Presenter: Do-Youn Oh
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-center, single-arm, phase II study
Presenter: Yiming Zhao
Session: Poster Display session
Resources:
Abstract
137P - A single-arm, multicenter, phase II study of hepatic arterial infusion chemotherapy (HAIC) combined with donafenib and sintilimab as first-line treatment for unresectable intrahepatic cholangiocarcinoma (CHANCE 2203)
Presenter: Gaojun Teng
Session: Poster Display session
Resources:
Abstract
139P - KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC)
Presenter: Makoto Ueno
Session: Poster Display session
Resources:
Abstract
140P - Tinengotinib (TT-00420) in combination with atezolizumab (atezo) in Chinese patients (pts) with biliary tract carcinoma (BTC): Efficacy and safety results from a phase Ib/II study
Presenter: Panpan Zhang
Session: Poster Display session
Resources:
Abstract
141P - Predictive MINT pathological risk score for adjuvant chemotherapy in resected cholangiocarcinoma: A propensity score matched multicenter study in Thailand
Presenter: Kaewta Jeerapradit
Session: Poster Display session
Resources:
Abstract